Stiefel Extends PanOxyl Line With Former Rx Acne Washes
This article was originally published in The Tan Sheet
Executive Summary
Stiefel Laboratories extends its PanOxyl skin care line with two previously Rx acne products that will debut over-the-counter this spring.
You may also be interested in...
Crown Labs Spreads Out, GSK Narrows Focus In OTC Skin Care Brand Deal
GSK further narrows consumer health focus with sale to Crown Labs of North American distribution rights for PanOxyl acne wash, Sarna anti-itch lotion, Zeasorb anti-fungal product, Desenex athlete’s foot treatment and Mineral Ice pain-relieving gel. Deals also helps UK pharma pay for its $5.1bn acquisition of oncology drug firm Tesaro.
Crown Labs Spreads Out, GSK Narrows Focus In OTC Skin Care Brand Deal
GSK further narrows consumer health focus with sale to Crown Labs of North American distribution rights for PanOxyl acne wash, Sarna anti-itch lotion, Zeasorb anti-fungal product, Desenex athlete’s foot treatment and Mineral Ice pain-relieving gel. Deals also helps UK pharma pay for its $5.1bn acquisition of oncology drug firm Tesaro.
Glaxo Subsidiary Stiefel’s Former CEO Faces Securities Fraud Charges
The Securities and Exchange Commission alleges Charles Stiefel, former chairman and CEO of family-owned Stiefel Labs, did not disclose to employee-shareholders material information on the value of the firm’s shares as the firm bought back shares before being acquired by GlaxoSmithKline.